Effects of the Peroxisome Proliferator Di(2-Ethylhexyl)Phthalate on Enzymes in Rat Liver and on Carcinogen-Induced Liver Altered Foci in Comparison to the Promoter Phenobarbital
Free accessResearch articleFirst published online February, 1990
Effects of the Peroxisome Proliferator Di(2-Ethylhexyl)Phthalate on Enzymes in Rat Liver and on Carcinogen-Induced Liver Altered Foci in Comparison to the Promoter Phenobarbital
The livers of rats given either the peroxisome proliferating hepatocarcinogen di(2-ethylhexyl)phthalate (DEHP) following initiation by 2-acetylaminofluorene (AAF) or the neoplasm promoter phenobarbital (PB) were studied for changes in 8 histochemical properties. Male F344 rats were fed 200 ppm AAF for 7 weeks to induce hepatoccllular altered foci, and were then fed diets containing either no chemical, 12,000 ppm DEHP or 500 ppm PB for 24 weeks. In hepatocytes, DEHP increased alkaline phosphatase activity throughout the lobule, but reduced gamma-glutamyltransferase (GGT) activity in periportal hepatocytes. PB, in contrast, increased GGT activity in periportal hepatocytes. In foci that were induced by AAF, DEHP reduced the histochemical activity of GGT and did not increase the number, mean volume or volume % of foci detected by deficiencies in iron storage, glucose-6-phosphatase, adenosine triphosphatase or fibronectin. PB enhanced the expression of all 8 phenotypic abnormalities in foci such that either more profiles were detected or the area of foci was increased.
1. Bannasch P (1986). Preneoplastic lesions as end points in carcinogcnicity testing. 1 Hepatic preneoplasia.Carcinogenesis7: 689–695.
2.
2. Berenblum I (1974). Carcinogenesis as a Biological Problem. Frontiers of Biology, Vol. 34. A. Neuberger and E. L. Tatum (eds) North-Holland Publishing Co., Amsterdam.
3.
3. Burstone MS (1961). Histochemical demonstration of phosphatases in frozen section with naphthol A,A-phosphates.J. Histochem. Cytochem.9: 146–153.
4.
4. Campbell HA, Pitot HC, Potter VR, and Laishes BA (1982). Application of quantitative sterology to the evaluation of enzyme-altered foci in rat liver.Cancer Res.42: 465–472.
5.
5. DcAngelo AB, Queral AE, and Garett CT (1985). Concentration-dependent inhibition of development of GGT positive foci in rat liver by the environmental contaminant di(2-ethylhexyl)phthalate.Environ. Health Perspec.60: 381–385.
6.
6. Delellis RA, Sternberg LA, Mann RB, Tanks PM, and Nakane PK (1979). Immunoperoxidase technics in diagnostic pathology.Am. J. Clin. Pathol.71: 483–488.
7.
7. Furukawa K, Maeura Y, Furukawa NT, and Williams GM (1983). Induction by butylated hydroxytoluene of rat liver gamma-glutamyltranspeptidase activity in comparison to expression in carcinogen-induced altered lesions.Chem. Biol. Interact.48: 43–58.
8.
8. Furukawa K, Numoto S, Furuya K, Furukawa NT, and Williams GM (1985). Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of pheno-barbital.Cancer Res.45: 5011–5019.
9.
9. Glauert HP, Beer D, Rao MS, Schwarz M, Zu YD, Goldsworthy TL, Coloma J, and Pitot HC (1986). Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome poliferators alone or following a single dose of diethylnitrosamine.Cancer Res.46: 4601–4606.
10.
10. Gomori G (1952). Acid phosphatase. In: Microscopic Histochemistry, Principles and Practice.University Chicago Press, Chicago, p. 189.
11.
11. Kitagawa T, Imai F, and Sato K (1980). Re-evaluation of gamma-glutamyltranspeptidase activity in periportal hepatocytes of rats with age.Gann71: 362–366.
12.
12. Maruyama H, Tanaka T, Gebhardt R, Berghem L, and Williams GM (1988). Decreased fibronectin in rat liver altered foci and adenomas induced by N-2-fluorenylacetamide.Lab. Invest.58: 630–635.
13.
13. Mochizuki Y, Furukawa K, and Sawada N (1982). Effect of various concentrations of ethyl-p-chloro-phenoxyisobutylate (clofibrate) on diethylnitros-amine-induced hepatic tumorigenesis in the rat.Car-cinogenesis3: 1027–1029.
14.
14. Mopon P, Greaves P, Irisarri E, Monro AM, and Bridges JW (1987). A cytochemical study of the livers of rats treated with diethylnitrosamine/phenobarbi-tal, with benzidine/phenobarbital, with phenobarbi-tal, or with clofibrate.Toxicology46: 217–236.
15.
15. Novikoff AB, Novikoff PM, Davis C, and Quintant N (1972). Studies on microperonisomes. II. A cytochemical method for light and electron microscopy.J. Histochem. Cytochem.20: 1006–1023.
16.
16. Numoto S, Furukawa K, Furuya K, and Williams GM (1984). Effects of the hepatocarcinogenic per-oxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis.Carcinogenesis5: 1603–1611.
17.
17. Numoto S, Mori H, Furuya K, Levine W, and Williams GM (1985). Absence of promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide.Toxicol. Appl. Pharmacol.77: 76–85.
18.
18. Ogawa K, Onoe T, and Takeuchi M (1981). Spontaneous occurrence of gamma-glutamyltranspepti-dase-positive hepatocytic foci in 105-week-old Wis-tar and 72-week-old Fischer 344 male rats.J. Natl. Cancer Inst.67: 407–412.
19.
19. Perera MER, and Shinozuka H (1984). Accelerated regression of carcinogen-induced preneoplastic he-patocyte foci by peroxisome proliferators BR931 and di-2-ethyl-hexylphthalate.Carcinogenesis5: 1193–1198.
20.
20. Popp JA, Garvey LK, Hamm TE Jr and Swenberg JA (1985). Lack of hepatic promotional activity by the peroxisomal proliferating hepatocarcinogen di(2-ethylhexyl)phthalate.Carcinogenesis6: 141–144.
21.
21. Preat V, Gerlach JD, Lans M, Taper H, and Roberfroid M (1986). Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichloroethane, butylated hydroxytoulene and nafenopin on rat hepatocarcinogenesis.Carcinogenesis7: 1025–1028.
22.
22. Rao MS, Lalwani MD, Scarpelli DG, and Reddy JK, (1982). The absence of gamma-glutamyltranspeptidase activity in putative preneoplastic lesions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator Wy-14,643.Carcinogenesis3: 1231–1233.
23.
23. Reddy JK and Rao MS (1978); Enhancement by Wy-14,643, a hepatic peroxisome proliferator, of dieth-ylnitrosamine-initiated hepatic tumorigenesis in the rat.Br. J. Cancer38: 537–563.
24.
24. Remandet B, Gouy D, Berthe J, Mazue G, and Wil-. liams GM (1984). Lack of initiating or promoting activity of six benzodiazepine tranquilizers in rat liver limited bioassays monitored by histopathology and assay of liver and plasma enzymes.Fund. Appl. Toxicol.4: 152–163.
25.
25. Schulte-Hermann R (1985). Tumor promotion in the liver.Arch. Toxicol.57: 147–158.
26.
26. Stäubli W, Bently P, Bieri F, Frohlich E, and Waech-ter F (1984). Inhibitory effect of nafenopin upon the development of diethylnitrosamine-induced enzyme-altered foci within the rat liver.Carcinogenesis5: 41–46.
27.
27. Stewart HL, Williams GM, Keyaser CH, Lombard LS, and Montali RJ (1980). Histologic typing of liver tumors of the rat.J. Natl. Cancer Inst.64: 177–207.
28.
28. Wachstein M and Meisel E (1957). On the histo-chemical demonstration of glucose-6-phosphatasc.J. Histochem. Cytochem.4: 592.
29.
29. Wachstein M and Meisel E (1957). Histochemistry of hepatic phosphatase at a physiological pH with special reference to the demonstration of bile canaliculi.Am. J. Clin. Pathol.27: 12–23.
30.
30. Walli A and Seidel D (1981). Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.Res. Exp. A fed.179: 15–161.
31.
31. Ward JM, Rice JM, Creasia D, Lynch P, and Riggs C (1983). Dissimilar patterns of promotion by di(2-ethylhexyl)phthalatc and phcnobarbital of hepato-cellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice.Carcinogenesis4: 1021–1029.
32.
32. Watanabe K and Williams GM (1978). The enhancement of rat hepatocellular altered foci by the liver tumor promoter phenobarbital: Evidence that foci are precursors of neoplasms and that the promoters act on carcinogen-induced lesions.J. Natl. Cancer Inst.61: 1311–1314.
33.
33. Weibel ER (1979). Stereological methods. Practical Methods for Biological Morphometry, Vol. 1. Academic Press, London.
34.
34. Williams GM (1982). Phenotypic properties of preneoplastic rat liver lesions and applications to detection of carcinogens and tumor promoters.Toxicol. Pathol.10: 3–10.
35.
35. Williams GM (1984). Modulation of chemical carcinogenesis by xenobiotics.Fundam. Appl. Toxicol.4: 325–344.
36.
36. Williams GM (1980). The pathogenesis of rat liver cancer caused by chemical carcinogens.Biochem. Biophys. Acta605: 167–190.
37.
37. Williams GM, Hirota N, and Rice JM (1979). The resistance of spontaneous mouse hepatocellular neoplasms to iron-accumulation during rapid iron-loading by parenteral administration and their transplant-ability.Am. J. Pathol.94: 65–74.
38.
38. Williams GM, Katayama S, and Ohmori T (1981). Enhancement of hepatocarcinogenesis by sequential administration of chemical: Summation, versus promotion effects.Carcinogenesis2: 1111–1117.
39.
39. Williams GM, Maruyama H, and Tanaka T (1987). Lack of initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis.Carcinogenesis8: 875–880.
40.
40. Williams GM, Tanaka T, and Maeura Y (1986). Dose-related inhibition of aflatoxin B1 induced hepatocarcinogenesis by the phenolic antioxidants, butylated hydroxyanisole and butylated hydroxytoluene.Carcinogenesis7: 1043–1050.
41.
41. Williams GM and Watanabe K (1978). Quantitative kinetics of development of N-2-fluorcnylacetamide-induced altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen.J. Natl. Cancer Inst.61: 113–121.
